Coverage with evidence development for anti-Aβ mAb treatment in Alzheimer's patients
Official title: Prospective Study on Anti-Amyloid-β Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease Coverage of Evidence Development (The Anti-Aβ mAb CED Study)
Run by Centers for Medicare and Medicaid Services/ Coverage and Analysis Group · NCT06058234 · Data updated 2026-11-12
This study is testing how well a new Alzheimer's treatment works and its safety by tracking the progress of people with mild Alzheimer's or mild cognitive impairment over two years.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 8680 (estimated) |
| Sponsor | Centers for Medicare and Medicaid Services/ Coverage and Analysis Group Federal |
| Locations | 1 site (Baltimore, Maryland) |
| Status | Recruiting |
| Started | July 6, 2023 |
| Main results expected | June 30, 2028 |
| Study ends | June 30, 2029 |
| Registry record updated | September 28, 2023 |
| Trial ID | NCT06058234 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are Medicare patients with a clinical diagnosis of mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's dementia, confirmed by amyloid pathology.
✕Probably not a fit
Patients who do not have a clinical diagnosis of mild cognitive impairment or mild Alzheimer's dementia, or those without confirmed amyloid pathology, may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study is a prospective, longitudinal observational study that collects clinical data, patient assessments, and administrative claims data from Medicare beneficiaries diagnosed with mild Alzheimer's disease or mild cognitive impairment due to Alzheimer's disease. Clinicians will evaluate patients to confirm eligibility based on neurocognitive assessments and biomarker testing for amyloid presence. Data on cognition, function, and treatment-related outcomes will be submitted to a registry every six months for up to 24 months, allowing for comprehensive monitoring of treatment effects and safety. The study aims to align with the National Coverage Determination for monoclonal antibodies targeting amyloid in Alzheimer's disease.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the effectiveness and safety of anti-Aβ mAb treatments for patients with mild Alzheimer's disease and mild cognitive impairment.
How similar studies have gone: Other studies investigating monoclonal antibodies targeting amyloid have shown promise, but this specific approach of coverage with evidence development is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Medicare patients with a clinical diagnosis of mild cognitive impairment due to Alzheimer's disease (AD) or mild AD dementia, both with confirmed presence of amyloid beta pathology consistent with AD. Exclusion Criteria: * none
Where it's running
-
Centers for Medicare and Medicaid Services
Baltimore, Maryland, United States Recruiting
Study contacts
- Study coordinator: Cms Cag
- Email: CMS_caginquiries@cms.hhs.gov
- Phone: 410-786-2281
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
LIFU to Help Sleep and Amyloid Reduction in Older Adults with Cognitive Impairment
A wearable ultrasound device (ATTN201) is being tested to see if it’s safe and easy to use for people 65 and older with mild cognitive impairment and amyloid buildup.
-
Longitudinal profiling of plasma-derived glial extracellular vesicles in Alzheimer's disease
This study tests whether plasma glial extracellular vesicles and neuroinflammation biomarkers change over time across the Alzheimer’s disease spectrum and whether these signals relate to amyloid, tau, and neurodegeneration, with an additional step of exposing healthy iPSC-derived neurons to vesicles to see potential ne
-
Gut methane and Parkinson's: measuring if a probiotic helps people with Parkinson's, REM sleep behavior disorder, or cognitive concerns
This study tests whether a probiotic containing Limosilactobacillus reuteri can help people with Parkinson's disease, those at high risk for PD, and related cognitive issues by potentially improving gut methane levels and overall symptoms.
-
Non-invasive brain stimulation to try to improve memory in early Alzheimer's
Scientists test whether repetitive transcranial magnetic stimulation to the cerebellum can help short-term memory in people with early Alzheimer's disease compared with a sham procedure.
-
Leronlimab for brain inflammation in Alzheimer's disease
This study will test whether weekly injections of leronlimab are safe and can reduce brain inflammation in people over 50 with Alzheimer's disease or mild cognitive impairment due to Alzheimer's.
-
Mindfulness meditation for improving cognition in older adults
This study is testing whether mindfulness meditation can help older adults, including those with mild cognitive impairment, improve their thinking, memory, and overall quality of life.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.